Does diacylglycerol accumulation in fatty liver disease cause hepatic insulin resistance?

Brian N. Finck
Washington University School of Medicine in St. Louis

Angela M. Hall
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation
Finck, Brian N. and Hall, Angela M., "Does diacylglycerol accumulation in fatty liver disease cause hepatic insulin resistance?." BioMed Research International. 2015, 1-7. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/4181

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Review Article

Does Diacylglycerol Accumulation in Fatty Liver Disease Cause Hepatic Insulin Resistance?

Brian N. Finck and Angela M. Hall

Washington University School of Medicine, St. Louis, MO 63110, USA

Correspondence should be addressed to Brian N. Finck; bfinck@dom.wustl.edu

Received 5 November 2014; Accepted 27 January 2015

Academic Editor: Federico Salomone

Copyright © 2015 B. N. Finck and A. M. Hall. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Numerous studies conducted on obese humans and various rodent models of obesity have identified a correlation between hepatic lipid content and the development of insulin resistance in liver and other tissues. Despite a large body of the literature on this topic, the cause and effect relationship between hepatic steatosis and insulin resistance remains controversial. If, as many believe, lipid aggregation in liver drives insulin resistance and other metabolic abnormalities, there are significant unanswered questions as to which lipid mediators are causative in this cascade. Several published papers have now correlated levels of diacylglycerol (DAG), the penultimate intermediate in triglyceride synthesis, with development of insulin resistance and have postulated that this occurs via activation of protein kinase C signaling. Although many studies have confirmed this relationship, many others have reported a disconnect between DAG content and insulin resistance. It has been postulated that differences in methods for DAG measurement, DAG compartmentalization within the cell, or fatty acid composition of the DAG may explain these discrepancies. The purpose of this review is to compare and contrast some of the relevant findings in this area and to discuss a number of unanswered questions regarding the relationship between DAG and insulin resistance.

1. Introduction

Hepatic insulin resistance, lipid accumulation, and inflammation seem to be tightly interconnected. Indeed, strong correlations among these variables have been detected in obese human subjects and in studies conducted on a variety of mouse and rat models. However, the cause and effect relationship among these factors is not always clear and usually difficult to discern [1]. Furthermore, the largest genetic predictors of NAFLD are not always associated with hepatic insulin resistance [2, 3]. Experimental approaches to modulate the abundance of a given lipid unavoidably lead to changes in the abundance of other interconverted lipids such that manipulating the concentrations of one lipid in isolation seems impossible. Furthermore, difficulties in measuring the abundance of lipids present at very low levels and reproducibility across different model systems have raised questions regarding whether a specific lipid can be causally linked to development of insulin resistance. Whereas several lipids accumulate in steatotic liver, this review will focus on diacylglycerol (DAG), the evidence linking it to insulin resistance, and the controversy surrounding this linkage.

On the surface, DAG is a simple hydrophobic lipid that is normally a component of cellular membranes or is stored in lipid droplets. DAG is composed of a glycerol backbone and two fatty acyl groups. However, the biophysical properties and the physiological effects of DAG can be strongly influenced by the composition of the fatty acyl groups and its physical location within the cell. For example, acyl moieties can be esterified at either the sn-1,2 or the sn-1,3 positions of glycerol depending upon the pathway used to generate the DAG molecule. These two stereoisomers have different biophysical properties in membranes and previous work has shown that the sn-1,2 stereoisomer is much more potent, compared to sn-1,3-DAG, at activating certain signaling cascades linked to insulin resistance [4]. Accumulation of DAG containing saturated fatty acids has also been linked to development of insulin resistance. There is also correlative
evidence that the abundance of DAG in the various intracellular compartments (membrane versus lipid droplet) can be more strongly associated with insulin resistance [5, 6].

2. Connections between DAG and Insulin Resistance

Some of the original work correlating tissue DAG concentrations to insulin resistance was conducted in obese rats almost 25 years ago [7]. Based on previous work showing that phorbol ester, a DAG analog, could impair insulin action, Turinsky and colleagues hypothesized that endogenous DAG might be increased in insulin-resistant rodents. Measurement of DAG in obese Zucker rat tissues revealed that 1,2-DAG was elevated in multiple tissues in this model of type 2 diabetes. Since then, elevated DAG has been correlated to impaired insulin action in a variety of studies [8–13]. Ectopic accumulation of DAG in liver may be due to a variety of factors including consumption of a high fat or high sugar diet, inability of adipose tissue to appropriately store lipids leading to elevated circulating free fatty acids [14–16], or effects of oxidative stress in the liver causing DAG formation [17–19]. Because many lipids accumulate ectopically in obesity, which is correlated with insulin resistance, a variety of lipid species can be correlated with insulin resistance in obese animal models or humans. However, much of the recent attention in this area has focused on DAG due to the identification of clear mechanisms linking DAG to impaired insulin signaling.

Specifically, DAG has been shown in a variety of model systems to activate protein kinase C (PKC) family kinases, which physically interact with membrane-embedded DAG [20]. In hepatocytes or intact liver, links among DAG accumulation, PKC activation, and impaired insulin action have been made for PKCε [21] and PKCδ [22]. The mechanism of PKCε inhibition of insulin action was mediated via a direct interaction of PKCε with the insulin receptor to inhibit its intrinsic kinase activity [21] (Figure 1). The link between PKCε activation and hepatic insulin resistance is supported in correlative fashion by several papers [12, 13, 16, 23, 24] and in more convincing fashion by “knocking down” PKCε in liver by RNAi [21]. PKCε knockout mice exhibit improved glycemic control on a high fat diet, but this is likely mediated via enhanced insulin secretion [25]. PKCδ is also activated in steatotic liver [22, 25] and PKCδ knockout mice are protected from high fat diet induced hepatic steatosis while PKCδ overexpression was sufficient to drive insulin resistance [22].

As delineated above, numerous studies have correlated altered DAG concentrations to PKC activation and insulin resistance. However, it should be noted that several notable exceptions to these correlations have been detected where DAG accumulation in liver was not associated with development of insulin resistance [26–33]. One interpretation of these data is that DAG elevation is not, per se, sufficient to cause insulin resistance. The caveat to this conclusion is that it is not always clear whether all species, stereoisomers, or subcellular compartments are affected similarly. Could a change in the ratio or absolute amounts of sn-1,2 and sn-1,3 affect downstream signaling cascade activity? Similarly, could the chain length and degree of saturation also impact interpretation of these findings? Lastly, the subcellular compartmentalization of DAG has been reported to impact whether DAG accumulation drives insulin resistance or not [5, 6].

Though a large number of studies have examined the correlation between DAG and insulin resistance, this review is going to focus primarily on data generated by targeting enzymes that directly synthesize or degrade DAG. These studies were mostly conducted in animal models with gene deletion, gene expression knockdown, or overexpression. As discussed below, there are multiple enzymatic reactions involving glycerolipid and phosphoglycerolipid substrates that can result in DAG synthesis. The compartmentalization of many of these pathways, the substrate used, and the subcellular location where the reaction occurs could influence the resulting effect on metabolism and signaling. Moreover, despite the focus on enzymes that directly regulate DAG synthesis or turnover, this is not to say that other lipids derived from DAG or substrates for DAG synthesis are not affected. Indeed, as noted above, it is practically impossible to affect the concentration of one lipid in isolation.

3. Mechanisms for DAG Synthesis

In the liver, one of the primary pathways for synthesizing DAG is from the dephosphorylation of ER membrane-embedded phosphatidic acid (PA) by the lipin family of proteins (lipin 1, lipin 2, and lipin 3) (Figure 2) [34, 35]. This pathway can only produce 1,2-DAG since PA is phosphorylated at the sn-3 position. Evidence exists that both lipin 1 and lipin 2 encode...
significant hepatic PAP activity [36] and may play a role in development of NAFLD and related metabolic abnormalities. Acute adenoviral-mediated knockdown of lipin 1 or lipin 2 was shown to reduce hepatic DAG, PKCe activation, and associated insulin resistance [37, 38]. However, when hepatic steatosis was examined in liver-specific lipin 1 knockout mice fed a diet containing high amounts of ethanol, alcoholic hepatic steatosis and liver diseases were exacerbated by lipin 1 deficiency [39]. Similarly, we have recently found that liver-specific lipin 1 knockout mice are not protected from hepatic steatosis and insulin resistance after high fat diet (our unpublished results). It is not clear whether these discordant results between knockout mouse studies and RNAi approaches are due to duration of lipin inhibition, chronic compensatory mechanisms, or some other experimental differences.

Monoacylglycerol acyltransferase enzymes (MGAT1, MGAT2, and MGAT3) also generate DAG by acylating monoacylglycerol (Figure 1), and both sn-1,2 and sn-1,3 DAG can be synthesized by MGAT enzymes. Recent work has suggested that the expression of genes encoding MGATs (Mogats) is markedly induced in human patients with NAFLD [40] as well as rodent models of obesity [29, 41]. Mogati knockdown or Mogat2 KO in mice led to a reversal of prevention of insulin resistance in high fat diet fed mice [29, 41–43]. Interestingly, Mogat knockdown in diet-induced obese mice, which caused a marked insulin sensitization, did not affect hepatic DAG content or compartmentalization [29, 42]. Despite this, membrane-associated PKC activity was reduced by Mogat knockdown, with the caveat that the PKC activity was not increased by the high fat diet compared to low fat controls [29].

Adipose tissue triglyceride lipase (ATGL) is a major hepatic triglyceride lipase [44]. Genetic deficiency in ATGL leads to ectopic lipid accumulation, due to the inability to mobilize stored triglycerides, in a number of tissues including the liver [28, 31]. ATGL deficiency led to hepatic steatosis, but this was not associated with development of hepatic insulin resistance, inflammation, or fibrosis [28, 31, 32, 45], despite the accumulation of DAG [31]. ATGL activity is also controlled by an enhancer protein called CGI-58 [46]. Knockdown of CGI-58 also resulted in accumulation of hepatic lipids, including DAG, but this did not cause insulin resistance in high fat diet fed mice [26]. A follow-up study concluded that loss of CGI-58 caused accumulation of DAG specifically in lipid droplets rather than ectopically in cell membranes, which prevented activation of PKCe signaling [6]. However, this contradicted another previous study by the same group showing a strong correlation between lipid droplet DAG content and insulin resistance in human liver [5]. These contradictory findings have not been reconciled.

4. Mechanisms for DAG Degradation

There are multiple enzymes that convert DAG to other chemical forms. This can be accomplished by addition or removal of a fatty acyl molecule or addition of a phosphate group. The effects of some of these pathways have now been examined by using transgenic mouse systems or RNAi methodology.

The terminal step in triglyceride synthesis is the diacylglycerol acyltransferases (DGAT1 and DGAT2). DGATs are well expressed in liver and have been targeted for gene deletion or knockdown by a number of studies. DGAT1 inhibition did not affect insulin sensitivity in high fat diet fed rats, while DGAT2 knockdown reduced hepatic lipid accumulation and improved hepatic and whole body insulin sensitivity [47]. The improvement in insulin sensitivity was correlated with a reduction in hepatic content of DAG and a corresponding reduction in PKCe activity [47]. Liver-specific overexpression of DGAT2 in transgenic mice somewhat surprisingly led to an accumulation of DAG and TAG but, interestingly, did not affect insulin sensitivity [27]. Subsequent analyses of these mice contradicted this and suggested that hepatic insulin sensitivity was impaired [11]. The discrepant results between the two studies have not yet been explained. It is also unclear why DGAT deficiency and overexpression had paradoxical effects on DAG content, though an unexpected increase in DAG was also observed with Mogat1 inhibition [29].

Hydrolysis of a fatty acyl group from DAG by fatty acid lipases is another way to degrade DAG to other chemical forms. Two genes encoding DAG lipases (Dagla and Daglb) have been cloned, but their role in the liver and in hepatic lipid homeostasis seems to be unknown. Hormone sensitive lipase (HSL) was once considered the primary triglyceride hydrolase but is now considered to be primarily a DAG lipase. HSL deficient mice exhibit increased hepatic insulin sensitivity with reduced hepatic triglyceride content [30, 48], while adenoviral-mediated overexpression of HSL also reduced hepatic steatosis [49]. It is not clear whether hepatic DAG content was affected by HSL loss or gain of function, and thus the evidence provided by these studies may not inform us about the linkage between DAG and insulin resistance.

DAG phosphorylation by DAG kinase to produce PA is another mechanism by which DAG concentrations could be...
affected. Whereas DAG kinase δ (DAGKδ) activity in skeletal muscle has been linked to obesity-related insulin resistance, no effect of diminished DAGKδ activity in liver was detected [50]. Could this mean that DAGKδ is not well expressed in liver or that another isoform of this family, of which there are many, could be the predominant form in liver? This has not been explored to our knowledge and it is not clear which, if any, DAGK family members are highly expressed in liver. Future studies may address this question.

5. Conclusions

The review of the relevant literature focused on enzymes that directly synthesize or metabolize DAG reveals a pattern of findings that is extremely mixed. Whereas some of the studies support a link between altered DAG content and insulin resistance through PKCs, other works fail to find a relationship. Again, there is an important limitation to interpreting data from this area; all of the generated data are essentially correlative. It is also unclear how the proposed mechanism for PKCe-mediated impairment in insulin action through inhibiting insulin receptor phosphorylation fits with the concept of selective insulin resistance [51]. Selective insulin resistance refers to the observation that although insulin-mediated suppression of gluconeogenic pathways is impaired in insulin-resistant liver, another pathway that stimulates de novo lipogenesis through the sterol response element binding protein (SREBP1) remains intact [51–54]. Though there are somewhat contradictory findings regarding at which step in the bifurcating insulin signaling cascades the selective insulin resistance occurs [52–54], it is generally believed to be downstream of the insulin receptor. Therefore, it is unclear how the PKCe-mediated impingement on insulin receptor activity fits with this widely observed concept and meshes into the broader model of hepatic insulin resistance. Future work will be needed to address these discrepancies and reconcile existing inconsistencies.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by NIH grants K01-DK087821 to Angela M. Hall and R01-DK078187 and R42-AA021228 to Brian N. Finck. The authors would like to thank all members of the lab, past and present, that contributed to this work with helpful discussions.

References

[1] R. V. Farese Jr., R. Zechner, C. B. Newgard, and T. C. Walther, “The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance,” Cell Metabolism, vol. 15, no. 5, pp. 570–573, 2012.
[2] Y. Zhou, G. Llauradó, M. Orešič, T. Hyötyläinen, M. Ortho-Melander, and H. Yki-Järvinen, “Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2,” Journal of Hepatology, 2014.
[3] S. Sookoian and C. J. Pirola, “Meta-analysis of the influence of I48M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease,” Hepatology, vol. 53, no. 6, pp. 1883–1894, 2011.
[4] R. R. Rando and N. Young, “The stereospecific activation of protein kinase C,” Biochemical and Biophysical Research Communications, vol. 122, no. 2, pp. 818–823, 1984.
[5] N. Kumashiro, D. M. Erion, D. Zhang et al., “Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 39, pp. 16381–16385, 2011.
[6] J. L. Cantley, T. Yoshimura, J. P. G. Camporez et al., “CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 5, pp. 1869–1874, 2013.
[7] J. Turinsky, D. M. O’Sullivan, and B. P. Bayly, “1,2-diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo,” Journal of Biological Chemistry, vol. 265, no. 28, pp. 16880–16885, 1990.
[8] A. L. Birkenfeld, H. Y. Lee, F. Guebre-Egziabher et al., “Deletion of the mammalian INDIY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice,” Cell Metabolism, vol. 14, no. 2, pp. 184–195, 2011.
[9] S. C. Choi, D. B. Savage, L. Abu-Elheiga et al., “Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 42, pp. 16480–16485, 2007.
[10] D. M. Erion, I. D. Ignatova, S. Yonemitsu et al., “Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein,” Cell Metabolism, vol. 10, no. 6, pp. 499–506, 2009.
[11] F. R. Jornayvaz, A. L. Birkenfeld, M. J. Jurczak et al., “Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 14, pp. 5748–5752, 2011.
[12] S. Neschen, K. Morino, L. E. Hammond et al., “Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice,” Cell Metabolism, vol. 2, no. 1, pp. 55–65, 2005.
[13] D. B. Savage, S. C. Cheol, V. T. Samuel et al., “Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 817–824, 2006.
[14] V. T. Samuel, Z.-X. Liu, X. Qu et al., “Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease,” Journal of Biological Chemistry, vol. 279, no. 31, pp. 32345–32353, 2004.
[15] K. L. Donnelly, C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks, “Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1343–1351, 2005.
[16] Y. Nagai, S. Yonemitsu, D. M. Erion et al., “The role of peroxisome proliferator-activated receptor γ coactivator-1 β in
the pathogenesis of fructose-induced insulin resistance," Cell Metabolism, vol. 9, no. 3, pp. 252–264, 2009.

[17] T. Nakajima and O. Yukawa, “Mechanism of radiation-induced diacylglycerol production in primary cultured rat hepatocytes,” Journal of Radiation Research, vol. 40, no. 2, pp. 135–144, 1999.

[18] K. Toriumi, Y. Horikoshi, R. Yoshibuki Osamura, Y. Yamamoto, N. Nakamura, and S. Takekoshi, “Carbon tetrachloride-induced hepatic injury through formation of oxidized diacylglycerol and activation of the PKC/NF-κB pathway,” Laboratory Investigation, vol. 93, no. 2, pp. 218–229, 2013.

[19] S. Yoon, Y. Maruyama, A. Kazusaka, and S. Fujita, “Accumulation of diacylglycerol induced by CCl4-derived radicals in rat liver membrane and its inhibition with radical trapping reagent—FT-IR spectroscopic and HPLC chromatographic observations,” Japanese Journal of Veterinary Research, vol. 47, no. 3–4, pp. 135–144, 2000.

[20] Y. Takai, A. Kishimoto, U. Kikkawa, T. Mori, and Y. Nishizuka, “Unsaturated diacylglycerol as a possible messenger for the activation of calcium-activated, phospholipid-dependent protein kinase system,” Biochemical and Biophysical Research Communications, vol. 91, no. 4, pp. 1218–1224, 1979.

[21] V. T. Samuel, Z.-X. Liu, A. Wang et al., “Inhibition of protein kinase Ce prevents hepatic insulin resistance in nonalcoholic fatty liver disease,” The Journal of Clinical Investigation, vol. 117, no. 3, pp. 739–745, 2007.

[22] O. Bezy, T. T. Tran, J. Pihlajamäki et al., “PKCδ regulates hepatic insulin sensitivity and hepatosteatosis in mice and humans,” Journal of Clinical Investigation, vol. 121, no. 6, pp. 2504–2517, 2011.

[23] D. M. Erion, S. Yonemitsu, Y. Nie et al., “SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 27, pp. 11288–11293, 2009.

[24] D. Zhang, Z.-X. Liu, S. C. Cheol et al., “Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 43, pp. 17075–17080, 2007.

[25] G. Frangioudakis, J. G. Burchfield, S. Narasimhan et al., “Diverse roles for protein kinase Cδ and protein kinase Cε in the generation of high-fat-diet-induced glucose intolerance in mice: regulation of lipogenesis by protein kinase Cδ,” Diabetologia, vol. 52, no. 12, pp. 2616–2620, 2009.

[26] J. M. Brown, J. L. Better, C. Lord et al., “CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance,” Journal of Lipid Research, vol. 51, no. 11, pp. 3306–3315, 2010.

[27] M. Monetti, M. C. Levin, M. J. Watt, et al., “Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT1 in the liver,” Cell Metabolism, vol. 6, no. 1, pp. 69–78, 2007.

[28] A. J. Hoy, C. R. Bruce, S. M. Turpin, A. J. Morris, M. A. Febbraio, and M. J. Watt, “Adipose triglyceride lipase-null mice are resistant to high-fat diet-induced insulin resistance despite reduced energy expenditure and ectopic lipid accumulation,” Endocrinology, vol. 152, no. 1, pp. 48–58, 2011.

[29] A. M. Hall, N. Soufi, K. T. Chambers et al., “Abrogating monoa-cylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice,” Diabetes, vol. 63, no. 7, pp. 2284–2296, 2014.

[30] P. J. Voshol, G. Haemmerle, D. M. Ouwens et al., “Increased hepatic insulin sensitivity together with decreased hepatic triglyceride stores in hormone-sensitive lipase-deficient mice,” Endocrinology, vol. 144, no. 8, pp. 3456–3462, 2003.

[31] S. M. Turpin, A. J. Hoy, R. D. Brown et al., “Adipose triacylglyc- erol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice,” Diabetologia, vol. 54, no. 1, pp. 146–156, 2011.

[32] K. T. Ong, M. T. Mashek, S. Y. Bu, and D. G. Mashek, “Hepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation,” The FASEB Journal, vol. 27, no. 1, pp. 313–321, 2013.

[33] Z. Sun, R. A. Miller, R. T. Patel et al., “Hepatic Hdad3 promotes gluconeogenesis by repressing lipid synthesis and sequestration,” Nature Medicine, vol. 18, no. 6, pp. 934–942, 2012.

[34] J. Donkor, M. Sariahmetoglu, J. Dewald, D. N. Brindley, and K. Reue, “Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns,” Journal of Biological Chemistry, vol. 282, no. 6, pp. 3450–3457, 2007.

[35] G.-S. Han, W.-I. Wu, and G. M. Carman, “The Saccharomyces cerevisiae lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme,” Journal of Biological Chemistry, vol. 281, no. 14, pp. 9210–9218, 2006.

[36] M. C. Gropler, T. E. Harris, A. M. Hall et al., “Lipin 2 is a liver-enriched phosphatidate phosphohydrolase enzyme that is dynamically regulated by fasting and obesity in mice,” The Journal of Biological Chemistry, vol. 284, no. 11, pp. 6763–6772, 2009.

[37] D. Ryu, K.-J. Oh, H.-Y. Jo et al., “TORC2 regulates hepatic insulin signaling via a mammalian phosphatidic acid phosphatase, LIPIN1,” Cell Metabolism, vol. 9, no. 3, pp. 240–251, 2009.

[38] D. Ryu, W.-Y. Seo, Y.-S. Yoon et al., “Endoplasmic reticulum stress promotes LIPIN2-dependent hepatic insulin resistance,” Diabetes, vol. 60, no. 4, pp. 1072–1081, 2011.

[39] M. Hu, H. Yin, M. S. Mitra et al., “Hepatic-specific lipin-1 deficiency exacerbates experimental alcohol-induced steatohepatitis in mice,” Hepatology, vol. 58, no. 6, pp. 1953–1963, 2013.

[40] A. M. Hall, K. Kou, Z. Chen et al., “Evidence for regulated monoa-cylglycerol acyltransferase expression and activity in human liver,” Journal of Lipid Research, vol. 53, no. 5, pp. 990–999, 2012.

[41] Y. J. Lee, E. H. Ko, J. E. Kim et al., “Nuclear receptor PPARγ-regulated monoa-cylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 34, pp. 13656–13661, 2012.

[42] N. Soufi, A. M. Hall, Z. Chen et al., “Inhibiting monoa-cylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice,” The Journal of Biological Chemistry, vol. 289, no. 43, pp. 30177–30188, 2014.

[43] C.-L. E. Yen, M.-L. Cheong, C. Grueter et al., “Deficiency of the intestinal enzyme acyl CoA:monoa-cylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding,” Nature Medicine, vol. 15, no. 4, pp. 442–446, 2009.

[44] R. Zimmermann, J. G. Strauss, G. Haemmerle et al., “Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase,” Science, vol. 306, no. 5700, pp. 1383–1386, 2004.

[45] J. W. Wu, S. P. Wang, F. Alvarez et al., “Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis,” Hepatology, vol. 54, no. 1, pp. 122–132, 2011.
A. Lass, R. Zimmermann, G. Haemmerle et al., “Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome,” *Cell Metabolism*, vol. 3, no. 5, pp. 309–319, 2006.

C. S. Choi, D. B. Savage, A. Kulkarni et al., “Suppression of diacylglycerol acyltransferase-2 (*DGAT2*), but not *DGAT1*, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance,” *The Journal of Biological Chemistry*, vol. 282, no. 31, pp. 22678–22688, 2007.

S. Y. Park, H. J. Kim, S. Wang et al., “Hormone-sensitive lipase knockout mice have increased hepatic insulin sensitivity and are protected from short-term diet-induced insulin resistance in skeletal muscle and heart,” *The American Journal of Physiology—Endocrinology and Metabolism*, vol. 289, no. 1, pp. E30–E39, 2005.

B. N. Reid, G. P. Ables, O. A. Otlivanchik et al., “Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis,” *The Journal of Biological Chemistry*, vol. 283, no. 19, pp. 13087–13099, 2008.

A. V. Chibalin, Y. Leng, E. Vieira et al., “Downregulation of diacylglycerol kinase delta contributes to hyperglycemia-induced insulin resistance,” *Cell*, vol. 132, no. 3, pp. 375–386, 2008.

M. S. Brown and J. L. Goldstein, “Selective versus total insulin resistance: a pathogenic paradox,” *Cell Metabolism*, vol. 7, no. 2, pp. 95–96, 2008.

R. K. Semple, A. Sleigh, P. R. Murgatroyd et al., “Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis,” *The Journal of Clinical Investigation*, vol. 119, no. 2, pp. 315–322, 2009.

E. J. Bae, J. Xu, D. Y. Oh et al., “Liver-specific p70 S6 kinase depletion protects against hepatic steatosis and systemic insulin resistance,” *Journal of Biological Chemistry*, vol. 287, no. 22, pp. 18769–18780, 2012.

S. Li, M. S. Brown, and J. L. Goldstein, “Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 8, pp. 3441–3446, 2010.
